Want to see HK:0241 full AI Analyst Report?
Top Page
Alibaba Health Information Technology
(0241)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$3.50
▲(9.37% Upside)
Action:Reiterated
Date:07/10/26
The score is primarily supported by strong financial performance—especially the very conservative balance sheet and improved profitability versus 2022. This is offset by weak technicals (price below key moving averages with negative MACD) and a valuation profile that is not clearly compelling (P/E ~24.6 with no dividend yield provided).
Positive Factors
Conservative balance sheet
Extremely low leverage provides durable financial flexibility, lowering insolvency and refinancing risk. This strengthens the firm's ability to fund investments, weather cyclical downturns, and support shareholder returns over the next 2–6 months without stressing cash flows.
Negative Factors
Weak cash conversion
Lower and volatile cash conversion reduces internal funding for capex, inventory and growth initiatives. Persistent gaps between accounting earnings and cash limits ability to sustainably increase payouts or absorb shocks, raising execution risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage provides durable financial flexibility, lowering insolvency and refinancing risk. This strengthens the firm's ability to fund investments, weather cyclical downturns, and support shareholder returns over the next 2–6 months without stressing cash flows.
Read all positive factors
Alibaba Health Information Technology (0241) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$50.77B
Dividend Yield2.19%
Average Volume (3M)81.98M
Price to Earnings (P/E)21.9
Beta (1Y)2.32
Revenue Growth14.03%
EPS Growth36.55%
CountryHK
Employees1,394
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.12
Shares Outstanding16,175,301,000
10 Day Avg. Volume66,983,510
30 Day Avg. Volume81,979,351
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)3.73
Price to Sales (P/S)1.94
P/FCF Ratio54.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)HK$38.61B
Alibaba Health Information Technology Business Overview & Revenue Model
Company Description
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The compa...
How the Company Makes Money
Alibaba Health primarily makes money by monetizing healthcare product sales and platform-based services. Key revenue streams generally include: (1) Direct sales of pharmaceutical and healthcare products: the company sells medicines and other healt...
Alibaba Health Information Technology Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.26B | 30.60B | 27.03B | 26.76B | 20.58B |
| Gross Profit | 8.21B | 7.43B | 5.90B | 5.70B | 4.11B |
| EBITDA | 1.44B | 1.62B | 999.05M | -24.48M | -188.12M |
| Net Income | 1.94B | 1.43B | 883.48M | 535.65M | -265.56M |
Balance Sheet | |||||
| Total Assets | 23.02B | 21.18B | 19.71B | 20.75B | 19.20B |
| Cash, Cash Equivalents and Short-Term Investments | 10.45B | 8.10B | 9.55B | 10.92B | 10.55B |
| Total Debt | 59.56M | 35.52M | 82.17M | 77.80M | 135.41M |
| Total Liabilities | 5.22B | 4.87B | 5.19B | 5.60B | 5.13B |
| Stockholders Equity | 17.80B | 16.31B | 14.54B | 15.17B | 14.10B |
Cash Flow | |||||
| Free Cash Flow | 1.23B | 1.38B | 1.06B | 250.08M | 409.43M |
| Operating Cash Flow | 1.24B | 1.40B | 1.08B | 255.69M | 424.36M |
| Investing Cash Flow | 2.02B | -2.60B | -4.88B | -532.44M | 1.87B |
| Financing Cash Flow | -14.22M | -72.52M | -1.98B | -111.28M | -58.63M |
Alibaba Health Information Technology Technical Analysis
Negative
3.20
Price Trends
3.21
Negative
3.47
Negative
4.36
Negative
Market Momentum
-0.04
Positive
45.47
Neutral
51.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0241, the sentiment is Negative. The current price of 3.2 is above the 20-day moving average (MA) of 3.19, below the 50-day MA of 3.21, and below the 200-day MA of 4.36, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.47 is Neutral, neither overbought nor oversold. The STOCH value of 51.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0241.
Alibaba Health Information Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.19B | 13.03 | 7.00% | 4.62% | 6.47% | 8.10% | |
65 Neutral | HK$50.02B | 5.97 | 8.33% | 5.03% | 2.78% | 7.71% | |
64 Neutral | HK$50.77B | 21.87 | 10.95% | 2.19% | 14.03% | 36.55% | |
55 Neutral | HK$64.61B | 12.78 | 6.21% | 5.86% | 8.02% | -17.74% | |
54 Neutral | HK$13.97B | 24.05 | 4.62% | 160.60% | 7.92% | 152.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.06B | 46.74 | 1.88% | 1.11% | 16.87% | ― |
* Healthcare Sector Average
HK:0241
Alibaba Health Information Technology
3.05
-3.64
-54.39%
HK:1833
Ping An Healthcare and Technology Company
6.19
-16.48
-72.71%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.51
-0.07
-0.64%
HK:1099
Sinopharm Group Co
15.70
-2.16
-12.09%
HK:2158
Yidu Tech, Inc.
3.59
-2.49
-40.92%
HK:2192
Medlive Technology Co., Ltd.
7.01
-6.29
-47.31%
Alibaba Health Information Technology Corporate Events
Alibaba Health Announces Resignation of Non-Executive Director Xu Haipeng
Jul 29, 2026
Alibaba Health Information Technology Limited has announced the resignation of non-executive director Mr. Xu Haipeng, effective July 29, 2026, as he plans to devote more time to his personal commitments and development. The board emphasized that M...
Alibaba Health Reshapes Board and Committees to Bolster Governance
Jul 29, 2026
Alibaba Health Information Technology Limited has updated its board composition, effective July 29, 2026, appointing Shen Difan as chairman and chief executive officer alongside executive director Sheng Mengyue and non-executive director Huang Jia...
Alibaba Health Plans Major Dividend Payout and AGM Votes on Capital and Governance
Jul 6, 2026
Alibaba Health Information Technology has called its annual general meeting for 7 August 2026 in Hangzhou, where shareholders will review the audited financial statements for the year ended 31 March 2026 and vote on director re-elections, remunera...
Alibaba Health Plans Bye-law Changes to Boost Dividend Flexibility and Align with HK Listing Reforms
Jun 30, 2026
Alibaba Health Information Technology Limited plans to amend its bye-laws to enhance board flexibility on dividend and distribution payments, including allowing distributions from contributed surplus in addition to profits, subject to shareholder ...
Alibaba Health Grants New Share Options and RSUs Under 2024 Award Scheme
Jun 15, 2026
Alibaba Health Information Technology has granted share-based incentives under its 2024 Share Award Scheme, issuing 2,283,500 share options to a connected grantee who is a director, and 56,464,500 restricted share units to 521 grantees. The move, ...
Alibaba Health Delivers Strong FY2026 Profit Growth and Advances Smart Healthcare Push
May 14, 2026
Alibaba Health Information Technology reported solid results for the year ended March 31, 2026, with revenue rising 12.0% to RMB34.26 billion and net profit jumping 35.2% to RMB1.94 billion. Adjusted net profit grew 19.3% to RMB2.33 billion, lifti...
Alibaba Health Declares Final Dividend for FY2026
May 14, 2026
Alibaba Health Information Technology has declared a final ordinary cash dividend of RMB 0.0595 per share for the financial year ended 31 March 2026, with the Hong Kong dollar equivalent and exchange rate to be announced. The dividend is subject t...
Alibaba Health Announces Special Dividend for FY2026
May 14, 2026
Alibaba Health Information Technology Limited has declared a special cash dividend of RMB 0.1352 per share for the financial year ended March 31, 2026, subject to shareholder approval on August 7, 2026. The dividend, with details of the Hong Kong ...
Alibaba Health Plans Share Premium Cut to Boost Dividend Capacity
May 14, 2026
Alibaba Health Information Technology plans to fund a newly recommended final and special dividend by reducing RMB10 billion from its share premium account and transferring the amount to its contributed surplus account, subject to shareholder appr...
Alibaba Health Names New CFO and Executive Director as Tu Yanwu Steps Down
May 14, 2026
Alibaba Health Information Technology has appointed Sheng Mengyue as executive director and chief financial officer, effective at the close of business on May 15, 2026, succeeding Tu Yanwu, who has resigned from both roles. Sheng brings more than ...
Alibaba Health Reshapes Board and Committee Roles Effective May 2026
May 14, 2026
Alibaba Health Information Technology Limited has updated the composition of its board of directors, effective after the close of business on May 15, 2026, confirming Shen Difan as chairman and chief executive officer alongside executive, non-exec...
Alibaba Health Sets May Board Meeting to Approve Annual Results and Consider Dividend
Apr 30, 2026
Alibaba Health Information Technology Limited has scheduled a board meeting for May 14, 2026, to review and approve the audited financial results for the year ended March 31, 2026. The board will also consider whether to recommend a final dividend...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.